Interferon alfa-2b

Interferon alfa-2b

Clinical data
MedlinePlus	a690006
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Subcutaneous, intramuscular
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Identifiers
ATC code	L03AB05 (WHO)
IUPHAR/BPS	8338
DrugBank	DB00105
ChemSpider	none
ChEMBL	CHEMBL1201558
(what is this?)  (verify)

Interferon alfa 2b is an antiviral drug originally discovered in the laboratory of Charles Weissmann at the University of Zurich, developed at Biogen, and ultimately marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.

This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.

Interferon alfa-2b products[1]
Product	Manufacturer	Features	Special uses
Alpharona	Pharmaclon
Intron-A/IntronA	Schering-Plough
Realderon	Teva
Reaferon EC	GNC Vector
Reaferon EC-Lipint	Vector-Medica	liposomal
Infagel	Vector-Medica	ointment
Recolin	Vector-Medica
Altevir	Bioprocess subsidiary	liquid, free of HSA
Kipferon	Alfarm	combination with IgM, IgA, IgG
Giaferon	A/S Vitafarma
Genferon	Biocad
Opthalamoferon	Firn-M	with dimedrol	eye infections

See also

• Interferon

References

1. Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2* (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J 2.

External links

• Intron-A Summary of Product Characteristics
• Nagata S, Taira H, Hall A, et al. (Mar 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature 284 (5754): 316–20. doi:10.1038/284316a0. PMID 6987533.